EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Safety of Metformin Continuation During Peri-Procedural Period of Coronary Angiography in Type 2 Diabetic Patients

Dana Hama-Baqi Mohammed-Saeed

Advanced Medical Journal · 2025

DOI: 10.56056/403 ↗
AbstractBibliografische Angaben

Abstract

Background The safety of maintaining metformin therapy in patients undergoing coronary angiography is a topic of ongoing debate. The present study aims to examine patients with type 2 diabetes who continued to use metformin while undergoing coronary angiography for the development of contrast-induced nephropathy and lactic acidosis. Patients and Methods This investigation was a cross-sectional study that was carried out in Sulaimani Cardiac Hospital between January 2023 to June 2023 that enrolled 100 patients with type 2 diabetes and baseline creatinine clearance more than 45 ml/min for whom elective coronary angiography was performed. Monitoring of renal function and clinical signs of lactic acidosis were observed. Results The majority of cases (57%) received less than 50 cc of contrast, followed by 50-150 cc in 32 cases. Only one patient, a 70-year-old woman with a baseline impaired creatinine level (1.4 mg/dL), developed contrast-induced nephropathy, and there was no statistically significant change in creatinine level. With vigilant monitoring and proper hydration, her renal function returned to baseline levels within 7 days after the angiogram. Furthermore, there was no lactic acidosis in any of the participants. Conclusion It appears to be safe to continue metformin therapy during coronary angiography for type 2 diabetic patients whose baseline creatinine clearance above 45 ml/min.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →